LCTX Lineage Cell Therapeutics Forecast, Technical & Fundamental Analysis
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases... Show more
LCTX is expected to report earnings to fall 33.33% to -1 cents per share on August 06
Q2'26
Est.
$-0.02
Q1'26
Missed
by $0.02
Q4'25
Beat
by $0.05
Q3'25
Missed
by $0.11
Q2'25
Missed
by $0.10
The last earnings report on May 12 showed earnings per share of -2 cents, missing the estimate of 0 cents. With 400.52K shares outstanding, the current market capitalization sits at 306.64M.
A.I. Advisor
published General Information
General Information
a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, and neurological conditions
A.I.dvisor indicates that over the last year, LCTX has been loosely correlated with MDGL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if LCTX jumps, then MDGL could also see price increases.
LCTX sees its Stochastic Oscillator ascending out of oversold territory
On June 11, 2026, the Stochastic Oscillator for LCTX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 76 instances where the indicator left the oversold zone. In of the 76 cases the stock moved higher in the following days. This puts the odds of a move higher at over .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where LCTX's RSI Oscillator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for LCTX just turned positive on June 08, 2026. Looking at past instances where LCTX's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LCTX advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LCTX as a result. In of 118 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for LCTX moved below the 200-day moving average on May 12, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LCTX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LCTX entered a downward trend on June 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.692) is normal, around the industry mean (18.816). P/E Ratio (0.000) is within average values for comparable stocks, (36.093). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.681). LCTX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (19.881) is also within normal values, averaging (359.668).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
